Prot# CENA713D2340: A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 & 15 cm2 Patch in Patients with Alzheimer's Disease Showing Cognitive Decline During an Init

Project: Research project

Project Details

StatusFinished
Effective start/end date7/10/076/30/11

Funding

  • Novartis Pharmaceuticals Corporation (CENA713D2340)